Neurology AdvisorEfficacy of Medications for Multiple Sclerosis-Related Fatigue

⚠️ Small Study / Early Comparative Evidence

MS-related fatigue is among the most disabling and treatment-resistant symptoms in the disease. This systematic review and network meta-analysis pooled 15 trials across 1,602 patients, evaluating pharmacologic treatments against two distinct outcome measures: fatigue severity (FSS) and fatigue-related functional impact (MFIS).

Clinical Considerations:

• No medication outperformed placebo on fatigue severity (FSS); N-acetylcysteine, modafinil, and aspirin ranked highest by P score but did not reach statistical significance
• Amantadine (MD −12.11) and fampridine (MD −14.05) showed statistically significant and potentially clinically meaningful MFIS improvements; methylphenidate reached significance but did not clear the minimally important difference threshold
• CBT and modafinil did not significantly improve fatigue-related functioning versus placebo on MFIS
• Evidence certainty was low to moderate across comparisons; heterogeneity limits direct cross-trial interpretation

Practice Applications:

• Consider amantadine or fampridine when the primary treatment target is functional fatigue burden rather than subjective severity
• Recognize that disability level, comorbid depression, and sleep disorders should shape individual medication selection
• Avoid interpreting statistical significance on MFIS as interchangeable with clinical meaningfulness; methylphenidate’s benefit did not clear the minimally important difference threshold
• Monitor emerging trial data; network meta-analysis findings here are hypothesis-strengthening, not practice-defining